New Cohort Study Data Shows Baxter's Expanded Hemodialysis - Known as HDx Therapy - is Associated With Approximately 25% Lower Mortality Rate for Up to Four Years
May 29, 2024
May 29, 2024
DEERFIELD, Illinois, May 29 (TNSres) -- Baxter International, a health care company that focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions, issued the following news release:
Baxter International Inc. (NYSE:BAX), a global innovator in kidney care and vital organ support, today announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximatel . . .
Baxter International Inc. (NYSE:BAX), a global innovator in kidney care and vital organ support, today announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximatel . . .